News: Products

In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEX^TM

08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron’s CustomEX™ drug delivery platform, at Cell 2023 in London.

Read more…

Creating a valuable and differentiated Exosome Delivery Platform

04 September 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.

Read more…

ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m

01 July 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, is pleased to announce that it has negotiated and signed a Supplemental Terms Agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) which has the potential to generate revenues of up to £6m for the Company.

Read more…

3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.

Read more…

Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed

18 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase 2a clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its Exosome technology.

Read more…

Progression with Fosun Pharma underscores commitment to CTX stroke disability programme

13 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that following on from the original Fosun Pharma (“Fosun”) licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme.

Read more…

11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

Read more…

30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.

Read more…

19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.

Read more…

ReNeuron collaborates with UCL to generate anti-cancer immune cells for cancer therapies

26 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that it has entered a collaboration agreement with University College London (‘UCL’) to conduct research into the generation of immune cells from induced pluripotent stem cells (‘iPSCs’) for anti-cancer cell therapies. ReNeuron will be working alongside Dr Claire Roddie, Associate Professor, UCL Cancer Institute, and the team at the UCL CAR-T cell cancer therapy programme.

Read more…